Shares of ImClone Systems ( IMCLE) were finding buyers in the premarket session Friday after the company and its prospective cancer drug Erbitux were mentioned positively in a published article. ImClone is preparing to discuss clinical data on Erbitux at this weekend's American Society of Clinical Oncology meeting, and The Wall Street Journal reported that doctors who have reviewed results of a new clinical trial of Erbitux say it confirms the findings of ImClone's study first presented two years ago. The Food and Drug Administration ultimately denied ImClone's drug application in December 2001, saying that an Erbitux clinical trial was deficient. ImClone's German partner Merck KGaA conducted the latest study. RealMoney columnist Adam Feuerstein reported earlier this month that sources familiar with Erbitux said the drug's performance in Merck's clinical trial was more positive than preliminary results had initially indicated. (Merck KGaA isn't affiliated with U.S. drugmaker Merck ( MRK).) The Journal wrote that Mark Pegram, an oncologist with UCLA, said on May 1 that anyone familiar with ImClone's previous Erbitux study won't be surprised by the new data to be presented Sunday. Though Friday's report didn't appear to contain new information, investors were encouraged by the positive press. Shares of ImClone were gaining $3.49, or 15%, to $26.95 on the Instinet platform before the opening bell. Since the start of the year, ImClone's shares have more than doubled.